US market expands for Glycosal diabetes test
This article was originally published in Clinica
Provalis has gained the green light to expand the US market for its Glycosal diabetes test after receiving FDA clearance to sell the test for prescription home use. The US has also granted the product CLIA (Clinical Laboratory Improvement Amendments) waiver status, a regulation designated to diagnostic tests that have been proven to be sufficiently simple and accurate to use, such that erroneous results in the hands of a non-medical user are extremely unlikely.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
HBW Market News: FTC Ends Another Supplement Scam, Australia Win For ChromaDex, GOED Report, Herbalife
Herbalife opens 9,200 square-foot training facility in China; GOED's latest annual market report, covering 2017-2018, is available; ChromaDex has two-tear exclusivity for nicotinamide riboside chloride in Australia; and A.S. Research arthritis claims for Synovia end in FTC settlement.
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.